Several reports noted that EGFR mutations were recognized in 15–20 % of patients with PPC but that the response to EGFR tyrosine kinase receptor inhibitor (TKI) was weak and transient as a consequence of tumor heterogeneity [8, 10, 11, 16–18]. This evidence concerns the gene EGFR and neoplasm.